Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025International Journal of Molecular SciencesOpen Access

Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

EAErhan AptullahogluEKEmrah Kaygusuz

Discussion

Loading...

Member takes

Overview

This research demonstrates enhanced anti-leukemic effects through MDM2 and STAT3 inhibition in ALL, suggesting new therapeutic strategies.

Key Points

  • Combination treatment with RG7388 and BBI608 significantly enhances apoptosis in ALL cell lines, targeting p53 wild-type and mutant contexts.
  • RG7388 effectively inhibits growth in most ALL cell lines, while BBI608 shows variable efficacy in reducing cell viability across tested lines.
  • Treatments highlight the importance of MDM2 and STAT3 inhibition as potential therapies for patients with acute lymphoblastic leukemia.
  • Findings indicate a need for further exploration of combinatorial therapeutic strategies for genetically diverse ALL patients.

Cite This Study

Aptullahoglu et al. (2025) studied this question.

synapsesocial.com/papers/68c192459b7b07f3a0616575https://doi.org/10.3390/ijms26178648
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2024 · 16 citations
  2. 2Targeted hyperactivation of oncogenic STAT5-signaling in acute lymphoblastic leukemia2025
  3. 3Data from Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia2024
  4. 4Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL2026 · 1 citations
  5. 5Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities2024 · 2 citations